Gilead's NASH combination treatment fails mid-stage study
Gilead Sciences Inc said on Monday all combinations of its three drugs to treat NASH were unsuccessful in a mid-stage study, the latest failure in a string of trials seeking to develop the first approved treatment for the fatty liver disease.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Fatty Liver Disease (FLD) | Health | Liver | Liver Disease | Study | Urology & Nephrology